Appointment of Christine Soden as Interim Chief Financial Officer

Back to press releases

LONDON, UK, 16 September 2009 – Optos plc (LSE: OPTS) a leading retinal imaging company,
today announces that following the recent departure of Allan M. Watson, Christine Soden joins the
Company on 22 September 2009 as Interim Chief Financial Officer. A search for a permanent
replacement continues.

Christine joins Optos from BTG plc, the FTSE250 specialty pharmaceuticals company. Christine
was appointed as Chief Financial Officer of BTG in 2005 and contributed significantly to the
company’s strategic, financial and operational development. Following the acquisition of
Protherics plc in December 2005, Christine became Chief Operating Officer of BTG and helped
integrate the two businesses.

There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial
Services Authority Listing Rules.

Roy Davis, Chief Executive Officer, said: “I am delighted to welcome Christine to Optos. She has
an excellent track record as both a CFO and senior board member in the life sciences industry and
brings a highly valuable skill set to help Optos during our year-end and as we seek to build on the
multiple opportunities available to Optos.”

Enquiries

Notes to Editors

About Optos Plc
Optos plc is a leading retinal imaging company with a vision to be recognized as the leading
provider of retinal diagnostics through leveraging its unique wide-field imaging technology. The
company has built an extensive installed base for its technology among healthcare professionals
under its pay-per-patient business model. This provides an excellent position from which to focus
on its core optometry business and expand into ophthalmology in a measured way. For more
information please visit www.optos.com

About Christine Soden
Christine joins Optos from BTG plc, the FTSE250 specialty pharmaceuticals company. Christine
was appointed as Chief Financial Officer of BTG in 2005 and contributed significantly to the
company’s strategic, financial and operational development. Following the acquisition of
Protherics plc in December 2005, Christine became Chief Operating Officer of BTG and helped
integrate the two businesses.

Prior to BTG, between 2000 and 2005, Christine was Chief Financial Officer at Oxagen Limited, a
privately owned drug discovery company; Christine helped refinance and restructure Oxagen.

From 1996 until 1999, Christine was Finance Director of Chiroscience Group plc before becoming
Chief Financial Officer of Celltech Chiroscience plc following the merger of the two companies.
During her time at Chiroscience she played a major role in fundraising, M&A, and licensing
(including the securing of six partnerships for drug development programmes).

Prior to this, Christine spent over four years as Group Financial Controller and Head of Tax and
Treasury at Medeva plc, where she was involved in acquisitions, financing and co-ordinating its US
stockmarket listing.

Christine has degree in mathematics from Durham University. After graduating she qualified as a
chartered account and worked for accountancy firms Clark Whitehill and Price Waterhouse. She
then spent eight years in a number of finance roles with investment group Pavion International plc
and Stringer Saul solicitors.

Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking
statements are not historical facts but rather are based on the Company's current expectations, estimates
and projections about its industry, its beliefs and assumptions. Words such as 'anticipates,' 'expects,'
'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forwardlooking
statements. These statements are not guarantees of future performance and are subject to known
and unknown risks, uncertainties and other factors, some of which are beyond the Company's control, are
difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the
forward-looking statements. The Company cautions shareholders and prospective shareholders not to place
undue reliance on these forward-looking statements, which reflect the view of the Company only as of the
date of this announcement. The forward-looking statements made in this announcement relate only to events
as of the date on which the statements are made. The Company will not undertake any obligation to release
publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or
unanticipated events occurring after the date of this announcement except as required by law or by any
appropriate regulatory authority.